Hormonal contraception, thrombosis and age

Lidegaard, Øjvind

doi:10.1517/14740338.2014.950654

Cited by 49 publications

(44 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, data were collected on smoking habits in the present study; no significant difference in peri-conception cigarette smoking or the length of cigarette smoking was found between the groups. It is known that combined hormonal contraceptive pills and smoking are both risk factors for venous thromboembolism, 17 and it could be hypothesized that individuals who smoke do not use oral contraceptives for longer periods;…”

Section: Discussionmentioning

confidence: 99%

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years

Horányi

Babay

Rigó

et al. 2017

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years

Horányi

Babay

Rigó

et al. 2017

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Yet, the potential advantage is that testing makes it possible to identify affected family members in whom the risk of first VTE can be lowered by preventive measures such as avoiding COC‐use . Suitable alternatives to COC‐use that have adequate contraceptive effectiveness are ovulation‐inhibiting progestogen‐only tablets, levonorgestrel‐containing intrauterine devices (IUDs) and Cu‐IUDs containing at least 300 mm 2 Cu .…”

Section: Discussionmentioning

confidence: 99%

Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta‐analysis

Vlijmen

Wiewel-Verschueren

Monster

et al. 2016

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: van Vlijmen EFW, Wiewel-Verschueren S, Monster TBM, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2016; 14: 1393-403. Essentials• We performed a meta-analysis on thrombosis risk in thrombophilic oral contraceptive (COC)-users.• The results support discouraging COC-use in women with a natural anticoagulant deficiency.• Contrary, additive risk of factor V Leiden (FVL) or prothrombin-G20210A (PT) mutation is modest.• Women with a FVL/PT-mutation as single risk factor can use COCs if alternatives are not tolerated. The cohort studies showed that absolute VTE risk was far higher in COC-users with severe thrombophilia than in those with mild thrombophilia (4.3 to 4.6 vs. 0.49 to 2.0 per 100 pill-years, respectively), and these differences in absolute risks were also noted in non-affected women (0.48 to 0.7 vs. 0.19 to 0.0), but with the caveat that absolute risks were estimated in relatives of thrombophilic patients with VTE (i.e. with a positive family history). Conclusion: These results support discouraging COC-use in women with severe hereditary thrombophilia. By contrast, additive VTE risk of mild thrombophilia is modest. When no other risk factors are present, (e.g. family history) COCs can be offered to these women when reliable alternative contraceptives are not tolerated.

show abstract

“…New generations of OC pills are characterized by lower estrogen content and by newer progestins, like desogestrel, gestodene, cyproterone, and drospirenone with lower androgenicity than past generation pills (52). They have been introduced to reduce severe adverse effects of OC use, especially thromboembolism, and other cardiovascular diseases (11). However, these new OC preparations are still associated with the risk of pulmonary embolism, myocardial infarction, thrombotic stroke and VTE (2,52).…”

Section: Impact Of the Composition Of The Contraceptive Pillmentioning

confidence: 99%

Increase of Oxidative Stress is Positively Associated with High-Sensitivity C-Reactive Protein in Women Using Combined Oral Contraceptives: An Observational Study

Cauci

Francescato

Colannino

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Information concerning oxidative stress and low-grade inflammation in oral contraception users is scarce. We investigated relationships of oxidative stress and high-sensitivity C-reactive protein (hsCRP) in women by oral combined contraceptive (OC) use. Methods Caucasian Italian healthy non-obese women (n = 290; 100 OC-users; 190 non-OC-users; mean age 23.2 ± 4.7 years) were analyzed. Blood hydroperoxides, as oxidative stress biomarkers, were assessed by Free Oxygen Radical Test (FORT), and serum hsCRP was determined by routine methods. Results Oxidative stress levels were elevated (≥ 400 FORT Units) in 77.0% and 15.8% of OC-users and non-OC-users, respectively (odds ratio (OR) = 209, 95%CI = 60.9-715.4, p < 0.001); hsCRP levels ≥ 2.0 mg/L were found in 41.0% and 9.5% of OC-users and non-users, respectively (OR = 6.6, 95%CI 3.5–12.4, p < 0.001). Continuous hydroperoxides values in OC-users were 1.7-fold higher compared to non-users (median 472 versus 270 FORT Units, p < 0.001); OC-users had 3.7-fold higher hsCRP values compared to non-OC-users (median 1.31 versus 0.35 mg/L, p < 0.001). Hydroperoxides were strongly positively correlated to hsCRP in all women (rs=0.622, p < 0.001), in OC-users (rs=0.442, p < 0.001), and in non-OC-users (rs=0.426, p < 0.001). Women with hydroperoxides ≥ 400 FORT Units were 8 times as likely to have hsCRP ≥ 2 mg/L. In non-OC-users only, hydroperoxides values were positively correlated with weight and body mass index, but negatively correlated with red meat, fish and chocolate consumption. Conclusions Our cross-sectional observational study is the first finding a strong positive correlation of serum hydroperoxides with hsCRP, a marker of inflammation. Further research is needed to elucidate the potential role of these two biomarkers in OC-use side-effects, like thromboembolism.

show abstract

Hormonal contraception, thrombosis and age

Cited by 49 publications

References 40 publications

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years

Effect of extended oral contraception use on the prevalence of fetal trisomy 21 in women aged at least 35 years

Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta‐analysis

Increase of Oxidative Stress is Positively Associated with High-Sensitivity C-Reactive Protein in Women Using Combined Oral Contraceptives: An Observational Study

Contact Info

Product

Resources

About